Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New developments in scleroderma interstitial lung disease.

Kristin B Highland1, Richard M Silver

  • 1Division of Pulmonary, Critical Care, Allergy and Clinical Immunology, Medical University of South Carolina, Charleston, SC 29425, USA. highlakb@musc.edu

Current Opinion in Rheumatology
|October 15, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis.

Annals of the rheumatic diseases·2026
Same author

Real-World Experience with Selexipag in Patients with Pulmonary Arterial Hypertension: Treatment Patterns and Outcomes across Baseline Risk Strata (SPHERE and EXPOSURE Studies).

Drugs - real world outcomes·2026
Same author

Interstitial pneumonia with autoimmune features: A literature review.

Respiratory medicine·2026
Same author

Initial Evaluation of Pulmonary Hypertension Functional Classification Self-Report Measurement Properties: A Patient-Focused Measure.

Chest·2025
Same author

Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis-Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.

ACR open rheumatology·2025
Same author

Characteristics of Patients with Pulmonary Arterial Hypertension Receiving Selexipag in the SPHERE Registry by Race and Ethnicity.

Journal of racial and ethnic health disparities·2025
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Systemic sclerosis-interstitial lung disease (SSc-ILD) research advances understanding of its causes and treatments. New insights into pathogenesis offer therapeutic targets for this major complication of systemic sclerosis.

Area of Science:

  • Pulmonary Medicine
  • Rheumatology
  • Immunology

Background:

  • Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in patients with systemic sclerosis (SSc).
  • Understanding the pathogenesis, clinical evaluation, and therapeutic options for SSc-ILD is crucial.

Purpose of the Study:

  • To review recent medical literature on interstitial lung disease associated with systemic sclerosis.
  • To highlight progress in understanding SSc-ILD pathogenesis, evaluation, and treatment.

Main Methods:

  • Literature review of recent studies on SSc-ILD.
  • Analysis of findings related to pathogenesis, clinical evaluation, and therapeutic interventions.

Main Results:

  • Microvascular disease, autoimmunity, and fibroblast activation are key in SSc-ILD pathogenesis.

Related Experiment Videos

  • The balance of pro- and anti-fibrotic mediators offers therapeutic opportunities.
  • High-resolution CT, bronchoalveolar lavage, and serum markers aid in assessing disease activity.
  • Treatment recommendations are limited by a lack of robust clinical trials, but studies like the Scleroderma Lung Study provide valuable data.

    • Conclusions:

    • Ongoing basic and clinical research in SSc-ILD is generating promising data.
    • These advancements are expected to lead to improved diagnostic and therapeutic strategies for SSc-ILD.